Maureen T. Tynan
University of North Carolina at Chapel Hill · 22 works · 629 citations · h-index 7
Top works
- Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
- Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
- A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
- Second-Line Gemcitabine in Refractory Stage IV Non–Small-Cell Lung Cancer: A Phase II Trial
- A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
- Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer
- Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC)
- P-576 A phase I/II trial of weekly docetaxel and gefitinib in elderlypatients (⩾70) with stage IIIB/IV non-small cell lung cancer (NSCLC)
- Randomized phase II trial comparing every-3-week carboplatin/paclitaxel (C/P) versus every-3-week C with weekly P in advanced non-small cell lung cancer (NSCLC)
- Phase Ib/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.
- Phase II trial of gemcitabine as second line therapy for non-small cell lung cancer (NSCLC)
- PD4-1-2: Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLS): preliminary report of a phase I/II trial
- P-251 Randomized phase II trial of weekly carboplatin/paclitaxel (C/P) versus every-3-week C/P in advanced non-small cell lung cancer (NSCLC): A pure schedule trial
- Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.
- Induction chemotherapy using carboplatin (C), irinotecan (I), and paclitaxel (P) with pegfilgrastim support followed by concurrent thoracic conformal radiation therapy (TCRT) with weekly CP and daily gefitinib
- Phase 1b/2 Study of Neoadjuvant Chemoradiation Therapy With CRLX101 and Capecitabine for Locally Advanced Rectal Cancer
- A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥ 70) with stage IIIB/IV non-small cell lung cancer (NSCLC)
- Feasibility of adjuvant carboplatin/docetaxel (C/D) in patients (pts) resected stage I-IIIB non-small cell lung cancer (NSCLC): Preliminary report of a phase II trial
- PPD4-2-6: Feasibility of Adjuvant carboplatin/docetaxel (C/D) in patients (pts) resected stage I-IIIB non-small cell lung cancer (NSCLS): Preliminary report of a phase II trial
- Induction Chemotherapy using Carboplatin(C), Irinotecan(I), and Paclitaxel(P) with Pegfilgrastim Followed by Concurrent Conformal Radiation Therapy (CRT) with Weekly Carboplatin/Paclitaxel and Daily Gefitinib (Iressa) Followed by Maintenance Gefitinib for Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)